Recursion Pharmaceuticals Inc
$ 3.71
-3.64%
11 Feb - close price
- Market Cap 2,006,862,000 USD
- Current Price $ 3.71
- High / Low $ 3.88 / 3.64
- Stock P/E N/A
- Book Value 2.13
- EPS -1.84
- Next Earning Report 2026-02-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.42 %
- ROE -0.91 %
- 52 Week High 12.36
- 52 Week Low 3.54
About
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.
Analyst Target Price
$7.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-05 | 2025-05-07 | 2025-02-25 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-02-27 | 2023-11-09 | 2023-08-08 | 2023-05-08 | 2023-02-27 |
| Reported EPS | -0.36 | -0.41 | -0.5 | -0.53 | -0.34 | -0.4 | -0.39 | -0.42 | -0.43 | -0.38 | -0.34 | -0.31 |
| Estimated EPS | -0.37 | -0.35 | -0.516 | -0.4168 | -0.35 | -0.4 | -0.42 | -0.45 | -0.38 | -0.37 | -0.35 | -0.29 |
| Surprise | 0.01 | -0.06 | 0.016 | -0.1132 | 0.01 | 0 | 0.03 | 0.03 | -0.05 | -0.01 | 0.01 | -0.02 |
| Surprise Percentage | 2.7027% | -17.1429% | 3.1008% | -27.1593% | 2.8571% | 0% | 7.1429% | 6.6667% | -13.1579% | -2.7027% | 2.8571% | -6.8966% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-27 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RXRX
2026-02-07 08:58:05
Borgeson Blake, a director at Recursion Pharmaceuticals (NASDAQ:RXRX), sold 220,000 shares for $924,000 on February 3, 2026, as per a Rule 10b5-1 trading plan. This sale occurred while RXRX shares had seen a 5% drop over the prior week and a 45% year-over-year decline. The company, despite holding more cash than debt, is not profitable and has a significant negative EBITDA.
2026-02-07 06:30:16
Director Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals (RXRX) for $924,000 on February 3, 2026, though the current stock price is below his selling price and the company faces profitability challenges despite holding more cash than debt. This sale occurred while the company reported promising Phase 1b/2 TUPELO trial results for REC-4881, leading JPMorgan to upgrade the stock to Overweight with an $11.00 price target. Recursion Pharmaceuticals plans to present updated clinical data from the TUPELO trial in a December 8, 2025 webinar to provide further insights into the drug's safety and efficacy for familial adenomatous polyposis (FAP).
2026-02-06 22:59:11
Director Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals (RXRX) for $924,000 on February 3, 2026, pursuant to a Rule 10b5-1 trading plan. This sale occurred as RXRX shares have declined, trading below Borgeson's selling price, despite recent promising TUPELO trial results for REC-4881 which led to a JPMorgan upgrade. The company, while cash-rich, is not profitable and has a negative EBITDA.
2026-01-26 21:28:02
Christopher Gibson, a director at Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 40,000 shares of Class A Common Stock for $178,800 and converted 40,000 Class B shares to Class A on January 20, 2026. Following these transactions, Gibson's direct and indirect holdings of Recursion Pharmaceuticals shares total over 1.7 million. This news comes as the company reported positive interim results for its investigational drug REC-4881 in treating familial adenomatous polyposis (FAP), leading to an "Overweight" upgrade from JPMorgan.
2026-01-25 21:33:18
Director Christopher Gibson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) sold 40,000 shares of Class A Common Stock for $178,800 on January 20, 2026, and converted an equal number of Class B shares to Class A. JPMorgan upgraded Recursion Pharmaceuticals to Overweight with an $11 price target due to positive results from its TUPELO trial for REC-4881, showing significant polyp reduction in FAP patients, with further clinical data to be presented. This article was generated with the support of AI and reviewed by an editor.
2026-01-25 09:01:05
Recursion Pharmaceuticals (RXRX) is gaining attention due to positive analyst commentary, insider buying, and a strategic AI partnership with Nvidia, despite a mixed share price performance over the past year. The company is at a critical juncture, transitioning from a "science project" to a commercial-stage TechBio leader with validated clinical data and significant milestone payments. While analysts suggest it could be undervalued by approximately 62.1% with a fair value of $12.49 per share, this optimistic outlook hinges on unproven long-term profitability and successful late-stage trial outcomes.
